GlobalData forecasts the seven major HIV markets will expand from $26.4 billion in 2023 to $30.6 billion by 2033, driven largely by the uptake of long-acting therapies. The shift toward extended-interval dosing aims to ease the lifelong pill burden, reduce treatment visibility, and improve patient adherence.
Market Growth and the Shift Toward Long-Acting Options
The human immunodeficiency virus treatment landscape is shifting. According to projections from pharma intelligence platform GlobalData, the HIV treatment market across the seven major markets—comprising the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan—is set to grow from $26.4 billion in 2023 to $30.6 billion by 2033.
This financial trajectory relies heavily on the commercial and clinical adoption of extended-interval drug regimens. While daily oral antiretroviral therapies remain the established standard of care for many individuals, experts indicate that reducing pill counts and minimizing treatment visibility are paramount concerns for those managing the condition according to GlobalData reporting.
“Long-acting HIV therapies are becoming an increasingly competitive treatment category. While efficacy remains essential, differentiation is now shifting towards factors such as dosing convenience, adherence benefits and the ability to improve the overall treatment experience for patients.”
Abigail Harris, infectious diseases analyst at GlobalData, via POZ
Clinical Data and Extended Dosing Milestones
Recent clinical findings continue to validate the move away from daily regimens. At the 26th International AIDS Conference (AIDS 2026), researchers shared positive data regarding ViiV Healthcare’s Cabenuva, a combination of cabotegravir and rilpivirine. As the first complete long-acting injectable treatment regimen to enter the market, Cabenuva holds approvals in the United States, the European Union, Japan, and Canada.
These results underscore the utility of injectables in tackling adherence hurdles inherent in lifelong daily care.
Concurrently, the regulatory framework in Europe has established paths for earlier injectable formulations. The European Medicines Agency’s human medicines committee adopted an opinion recommending marketing authorizations for Rekambys (rilpivirine) and Vocabria injection (cabotegravir) to be used together according to the European Medicines Agency. Intended for maintenance in adults with undetectable viral loads, these medicines require administration monthly or every two months.
Oral Alternatives and Pipeline Developments
Beyond injectables, research is expanding into once-weekly oral options. The candidate demonstrated non-inferiority in maintaining viral suppression compared to standard daily oral regimens when patients switched over.
Once-weekly pills provide distinct logistical benefits. However, their commercial viability will hinge on balancing affordability against the premium pricing typically commanded by enhanced dosing convenience.
Infrastructure, Access, and Economic Realities
Despite promising clinical performance, market analysts emphasize that wider adoption faces systemic hurdles.
For European patients, pricing decisions shift to individual member states once an EU-wide marketing authorization is granted according to regulatory notices from the European Medicines Agency. Ensuring equitable access across these diverse national health systems will require targeted pricing strategies and sustained investment to make certain that advanced formulations reach those who stand to gain the most.
Public Health Context and Long-Term Monitoring
The scale of the condition remains vast. The World Health Organization estimated that 38 million people were living with HIV worldwide in 2019 according to public health figures. Within the European Region, over 2.3 million cases have been diagnosed and reported over the past three decades, including upwards of 650,000 individuals inside the EU and European Economic Area.
Because long-acting formulations release active substances slowly over weeks, strict adherence to the dosing schedule is vital to prevent the virus from developing drug resistance the European Medicines Agency cautions. To monitor these risks post-approval, regulatory authorities require risk management plans, prospective cohort studies, and multi-year drug utilization studies to track safety profiles in real-world settings.
Related reading
